Last reviewed 2026-04-23 · How we verify

SpikoGen vaccine

SpikoGen is a recombinant protein vaccine designed to stimulate immune responses against SARS-CoV-2 spike protein.

SpikoGen is a recombinant protein vaccine designed to stimulate immune responses against SARS-CoV-2 spike protein. Used for COVID-19 prevention (SARS-CoV-2 infection).

At a glance

Mechanism of action

SpikoGen uses recombinant spike protein technology to train the immune system to recognize and respond to SARS-CoV-2. The vaccine aims to generate both antibody and T-cell mediated immunity against the viral spike protein, which is the primary target for neutralizing antibodies. This approach differs from mRNA and viral vector vaccines by using a directly manufactured protein antigen.

Approved indications

• COVID-19 prevention (SARS-CoV-2 infection)

Common side effects

• Injection site pain or swelling
• Fatigue
• Headache
• Myalgia
• Fever

Key clinical trials

• Covid-19 and Influenza Oral Vaccine Study (PHASE1)
• A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen) (PHASE3)
• Booster Study of SpikoGen COVID-19 Vaccine (PHASE3)
• Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine (PHASE2, PHASE3)
• Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine (NA)
• Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years (PHASE3)
• Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine (PHASE3)
• Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.